# Ohtuvayre (ensifentrine) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ensifentrine

> The FDA approved Ohtuvayre (ensifentrine), sponsored by Merck & Co., Inc. (MRK), on June 26, 2024 for to treat chronic obstructive pulmonary disease.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Ohtuvayre (ensifentrine) FDA approved?

Yes. The FDA approved Ohtuvayre (ensifentrine), sponsored by Merck & Co., Inc. (MRK), on June 26, 2024 for to treat chronic obstructive pulmonary disease. FDA novel drug approvals: "Ohtuvayre | ensifentrine | 6/26/2024 | To treat chronic obstructive pulmonary diseaseDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/ensifentrine)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/ensifentrine#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Ohtuvayre (ensifentrine) |
| Codes | MK-5884, RPL554 |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications | To treat chronic obstructive pulmonary disease, [Pulmonary Disease, Chronic Obstructive](https://sec-api.dev/indications/pulmonary-disease-chronic-obstructive) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### June 26, 2024: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat chronic obstructive pulmonary disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Ohtuvayre | ensifentrine | 6/26/2024 | To treat chronic obstructive pulmonary diseaseDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024
- openFDA Drugs@FDA: "NDA217389 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20240626, review_priority STANDARD; sponsor_name MSD; product OHTUVAYRE (ENSIFENTRINE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217389%22

### Apr to Jul 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Pulmonary Disease, Chronic Obstructive.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07874815 (Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-29 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07874815

### April 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Pulmonary Disease, Chronic Obstructive.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07874815 (Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-29 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07874815

## Same indication

- [Brenipatide](https://sec-api.dev/pdufa/brenipatide) (LLY)
- [Depemokimab](https://sec-api.dev/pdufa/depemokimab) (GSK)
- [GSK3862995B](https://sec-api.dev/pdufa/gsk3862995b) (GSK)
- [GSK5784283](https://sec-api.dev/pdufa/gsk5784283) (GSK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ensifentrine.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Ohtuvayre (ensifentrine) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ensifentrine

```bibtex
@misc{secapidev_pdufa_ensifentrine_20261116,
  title        = {Ohtuvayre (ensifentrine) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ensifentrine}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ensifentrine_20261116","title":"Ohtuvayre (ensifentrine) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ensifentrine","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
